The Complex Interplay Between COVID-19 and Glioblastoma Multiforme: Unveiling Causal Links and Clinical Implications

The COVID-19 pandemic has undoubtedly altered the landscape of global healthcare, revealing complex interactions between the novel coronavirus, SARS-CoV-2, and various pre-existing medical conditions.

Among these, the coexistence of cancer and COVID-19 has garnered significant attention due to its potential implications on disease susceptibility, severity, and prognosis. One particular area of concern is the relationship between COVID-19 and glioblastoma multiforme (GBM), a highly aggressive and malignant brain tumor.

Epidemiological studies have consistently identified cancer as an independent adverse prognostic factor for COVID-19. This risk is particularly pronounced in patients with GBM, owing to factors such as the higher incidence of GBM among the elderly population, frequent hospitalizations, and treatment-induced immunosuppression.

This confluence of factors creates a population vulnerable to both the devastating effects of GBM and the complications of COVID-19. As a result, expert groups have recommended tailored approaches to managing patients with high-grade gliomas during the pandemic.

Preliminary cross-sectional studies have also hinted at a potential biological vulnerability of GBM patients to COVID-19. However, establishing causality in this association has been challenging due to methodological biases and unmeasured confounders.

To address this issue, researchers have turned to Mendelian randomization (MR) analyses utilizing public genome-wide association study (GWAS) data to uncover potential causal relationships between COVID-19 and GBM susceptibility, hospitalization, and severity.

The MR analyses undertaken in this study have yielded compelling findings. Genetically predicted COVID-19 hospitalization risk was found to significantly increase the risk of GBM in the European population.

This discovery suggests a possible mechanistic link between the two conditions. Central to this connection is the role of certain receptors, specifically Alanyl aminopeptidase (ANPEP) and glutamyl aminopeptidase (ENPEP), which play crucial roles in the entry of SARS-CoV-2 into cells.

Increased distribution of these receptors in the endothelial cells of the blood-brain barrier could facilitate the entry of the virus into brain tissue, predisposing GBM patients to COVID-19 infection.

Interestingly, the potential mechanism behind this vulnerability is further substantiated by the presence of 27-hydroxycholesterol (27-OHC), a molecule that hampers viral entry into host cells. Elevated concentrations of 27-OHC during COVID-19 infection, while inhibiting the virus’s cellular entry, simultaneously promote the growth of GBM tumor cells. This intricate interaction underscores the complexity of the relationship between viral infections and tumor behavior.

Despite the observed link between genetically increased COVID-19 risk and GBM susceptibility, the MR analyses did not find an association between genetically predicted GBM risk and COVID-19 susceptibility, hospitalization, or severity in the European population. This discrepancy from earlier cross-sectional studies underscores the importance of considering confounding factors such as treatment-induced immunosuppression, neurological deficits, chronic use of steroids, and comorbidities, which might influence both cancer risk and COVID-19 outcomes.

The clinical implications of these findings are substantial. The study establishes that COVID-19 hospitalization significantly increases the risk of developing GBM. This insight underscores the need for enhanced prevention and evidence-based treatment strategies for COVID-19 in vulnerable patient populations. Furthermore, the lack of association between genetically predicted GBM risk and COVID-19 outcomes can inform more efficient allocation of medical resources.

However, this study is not without limitations. The mixed European ancestry of the study sample warrants further investigation across diverse ethnic groups. Additionally, the study does not account for potential pre-existing symptoms related to glioblastoma in COVID-19 patients, nor does it explore the timeline of risk emergence post-COVID-19 infection.

In conclusion, this study offers a deeper understanding of the intricate interplay between COVID-19 and GBM, shedding light on both causal links and clinical implications. The findings highlight the complex mechanisms through which SARS-CoV-2 may exploit pre-existing vulnerabilities in GBM patients, while also illustrating the absence of an association between genetically predicted GBM risk and COVID-19 outcomes.

However, additional research is needed to fully unravel the underlying mechanisms and implications of this association. Ultimately, this study contributes to the broader effort of optimizing medical responses to the multifaceted challenges posed by the COVID-19 pandemic.

---

reference link : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1185466/full